Then, developing AZIN1 inhibitor for cancer therapy may be superior to targeting polyamine synthetic pathway for the reason that inhibiting intracellular synthesis could lead to polyamine uptake from extracellular fluid by means of compensatory mechanism. The gene discussed is AZIN1; the disease is cancer.